Loading…
Getting the latest data.
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | Max |
|---|---|---|---|---|---|---|---|---|---|
| Total return | −0.6% | +2.7% | +0.4% | −10.4% | +9.4% | +9.8% | +76.8% | +17.4% | +27.8% |
| Peer average | 0.0% | +1.8% | +1.5% | −5.2% | +16.2% | +17.9% | +63.3% | +29.4% | — |
| S&P 500 · VOO | −0.4% | +2.6% | −2.3% | −2.1% | +11.5% | +11.6% | +79.3% | +72.7% | — |
$20 of every $1,000 in MMSC is Xometry,
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | XMTRXometry, () | Industrials | 2.03% | $202.51 | 8,628 | $1.0M |
| 2 | —US Dollar | — | 1.97% | $197.09 | 1.0M | $1.0M |
| 3 | FROGJFrog | Technology | 1.85% | $184.60 | 8,589 | $950K |
| 4 | ZETAZETA Global () | Technology | 1.76% | $176.31 | 24K | $907K |
| 5 | OLLIOllie's Bargain Outlet | Consumer Defensive | 1.50% | $149.67 | 8,127 | $770K |
| 6 | NTSKNetskope, () | Technology | 1.42% | $141.81 | 33K | $730K |
| 7 | VRNSVaronis Systems | Technology | 1.33% | $132.73 | 14K | $683K |
| 8 | TVTXTravere Therapeutics | Healthcare | 1.31% | $131.17 | 13K | $675K |
| 9 | SAILSailPoint | Technology | 1.29% | $128.51 | 32K | $661K |
| 10 | GHGuardant Health | Healthcare | 1.27% | $126.75 | 4,212 | $652K |
| 11 | SYRESpyre Therapeutics | Healthcare | 1.22% | $121.89 | 6,095 | $627K |
| 12 | PTGXProtagonist Therapeutics | Healthcare | 1.15% | $114.59 | 4,388 | $590K |
| 13 | LGNDLigand Pharmaceuticals () | Healthcare | 1.05% | $104.73 | 1,704 | $539K |
| 14 | RGENRepligen | Healthcare | 1.04% | $104.23 | 3,221 | $536K |
| 15 | PRAXPraxis Precision Medicines | Healthcare | 0.98% | $97.76 | 1,549 | $503K |
of the $580B in 112 Small cap ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | XMTR | Xometry, () | 2.03% |
| 2 | FROG | JFrog | 1.85% |
| 3 | ZETA | ZETA Global () | 1.76% |
| 4 | OLLI | Ollie's Bargain Outlet | 1.50% |
| 5 | NTSK | Netskope, () | 1.42% |
| 6 | VRNS | Varonis Systems | 1.33% |
| 7 | TVTX | Travere Therapeutics | 1.31% |
| 8 | SAIL | SailPoint | 1.29% |
| 9 | GH | Guardant Health | 1.27% |
| 10 | SYRE | Spyre Therapeutics | 1.22% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $0.0854 |